Metagenomics in Healthcare Market Report 2025

The metagenomics in healthcare market size has grown rapidly in recent years. It will grow from $2.07 billion in 2024 to $2.44 billion in 2025 at a compound annual growth rate (CAGR) of 17.9%. The growth in the historic period can be attributed to rising adoption of bioinformatics tools to analyze complex metagenomic data, increasing need for rapid and accurate pathogen detection methods, and growing use of metagenomics in drug discovery and biomarker identification.

The metagenomics in healthcare market size is expected to see rapid growth in the next few years. It will grow to $4.66 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to increasing prevalence of infectious diseases, rising demand for precision medicine, greater focus on antimicrobial resistance surveillance using metagenomics, expanding applications of metagenomics in oncology research and diagnostics, and growing awareness of microbiome-based therapies and interventions. Major trends in the forecast period include technological advancements in sequencing platforms, innovations in bioinformatics pipelines, developments in single-cell metagenomics, research and development in microbiome therapeutics, and integration of artificial intelligence in data analysis.

The increasing prevalence of infectious diseases is expected to drive the growth of the metagenomics in healthcare market. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, which can spread directly or indirectly between individuals. The rise in infectious disease prevalence is largely due to increased travel, which accelerates the spread of pathogens across regions and countries. Metagenomics in healthcare plays a crucial role in combating these diseases by enabling the rapid and accurate identification of pathogens, making it essential for managing infectious outbreaks. It reduces diagnostic uncertainty by analyzing complex microbial communities, improving patient outcomes, and facilitating targeted treatment approaches. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England rose by 10.7% in 2023, reaching 4,850 cases compared to 4,380 in 2022. Consequently, the growing prevalence of infectious diseases is driving the expansion of the metagenomics in healthcare market.

Leading companies in the metagenomics in healthcare market are developing innovative solutions, such as microbial community profiling. This method involves the comprehensive analysis of microbial populations in a specific sample, using sequencing and bioinformatics tools to assess their composition, diversity, and functional roles. For instance, in August 2024, MGI Tech Co. Ltd., a biotechnology company based in China, launched a Human Microbiome Metagenomics Sequencing Package. This package offers an automated, end-to-end workflow for microbial community profiling, making it easier to analyze human microbiome diversity and its link to various diseases. The package reduces manual labor, enhances reproducibility, and lowers costs, making large-scale and clinical microbiome research more accessible. Researchers benefit from faster and more precise microbial identification, as well as adaptable throughput, which aids in biomarker discovery and advances translational health research.

In May 2025, Mapmygenome India Limited, a genomics and diagnostics company based in India, acquired Microbiome Insights Inc. to expand its microbiome sequencing and analysis capabilities. With this acquisition, Mapmygenome aims to strengthen its presence in the North American market and enhance its offerings in personalized health, genomics, and research services. Microbiome Insights Inc., based in Canada, specializes in metagenomics for healthcare applications.

Major players in the metagenomics in healthcare market are F. Hoffmann-La Roche AG, Eurofins Scientific, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., BGI Genomics Co. Ltd., Novogene Corporation, Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., MedGenome Labs Limited, Zymo Research Corporation, BaseClear B.V., Psomagen Inc., Karius Inc., Microsynth AG, Macrogen Inc., Norgen Biotek Corp., Tiny Health Inc., CosmosID Inc., Kanvas Biosciences Inc., Phase Genomics Inc., and Wobble Genomics Inc.

North America was the largest region in the metagenomics in healthcare market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metagenomics in healthcare report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the metagenomics in healthcare market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Metagenomics in healthcare is the analysis of genetic material obtained directly from clinical or environmental samples to study entire microbial communities without the need for culturing. It aids in identifying pathogens, examining microbiome composition, and detecting disease-associated microbial changes, enabling accurate diagnosis, personalized therapy, and enhanced infection management.

The main types of metagenomics in healthcare are sample extraction kits and metagenomics kits. Sample extraction kits are commercially available tools designed to efficiently and reliably isolate deoxyribonucleic acid or ribonucleic acid from biological samples. It employs technologies such as next-generation sequencing, polymerase chain reaction, and microarray, and follows workflows including sample collection, deoxyribonucleic acid extraction, library preparation, and sequencing. It is applied in infectious disease diagnosis, genomic epidemiology, personalized medicine, microbiome analysis, and drug discovery, serving end users including hospitals, diagnostic laboratories, research institutes, pharmaceutical companies, and biotechnology companies.

The metagenomics in healthcare market research report is one of a series of new reports that provides metagenomics in healthcare market statistics, including metagenomics in the healthcare industry's global market size, regional shares, competitors with a metagenomics in healthcare market share, detailed metagenomics in healthcare market segments, market trends and opportunities, and any further data you may need to thrive in the metagenomics in healthcare industry. This metagenomics in healthcare market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metagenomics in healthcare market consists of revenues earned by entities by providing services such as bioinformatics analysis, microbial diagnostics, and drug discovery support. The market value includes the value of related goods sold by the service provider or included within the service offering. The metagenomics in the healthcare market also includes sales of sequencing platforms, reagents, consumables, and bioinformatics tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.